All In MedTech

Device Trial Radar · NCT07772232

Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia

Prospective Randomized Controlled Comparison of Holmium Laser Enucleation of the Prostate With Robotic Water Jet Ablation

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 3, 2026

Primary completion

Aug 3, 2029

Study completion Aug 3, 2033

Sponsor

Lead sponsor
The Methodist Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 19, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated device
Yes
Who can join
Male only, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares two FDA-approved surgical treatments for benign prostatic hyperplasia (BPH): Holmium Laser Enucleation of the Prostate (HoLEP) with MOSES 2.0 technology and Robotic Water Jet Ablation (RWJA) using the Hydros Robotic System. Men with BPH and prostate volumes between 50 and 180 mL will be randomly assigned to one of the two procedures. The study will measure changes in prostate volume, PSA, urinary flow, and bladder emptying at 12 months, along with safety, sexual function, continence, and healthcare utilization outcomes, which will be followed for up to 5 years after surgery.

Conditions

  • Benign Prostate Hypertrophy(BPH)
  • Lower Urinary Track Symptoms

Interventions

  • Device - HoLEP with MOSES 2.0Device

    Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.

  • RWJA with Hydros Robotic SystemDevice

    Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Prostate VolumeTime frame: Baseline and 12 months post-intervention
  2. Change in Prostate-Specific Antigen (PSA)Time frame: Baseline and 12 months post-intervention
  3. Change in Urinary Flow Rate (Qmax)Time frame: Baseline and 12 months post-intervention

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Houston Methodist

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.